CVS Health Corp

CVS

Equity

ISIN US1266501006 / Valor 548525

New York Stock Exchange, Inc (2024-11-20)

USD 56.83+1.90%

CVS Health Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

CVS Health Corp is a leading healthcare company that offers a wide range of services, including pharmacy benefits management, retail pharmacy, and healthcare clinics. The company has expanded its business through strategic acquisitions, such as Coram, Omnicare, Navarro Discount Pharmacy, and Target's pharmacies and clinics. In response to the COVID-19 pandemic, CVS has played a significant role in providing testing and vaccinations, partnering with the CDC to offer on-site vaccinations at nursing homes and assisted living facilities.

Summarized from source with an LLMView SourceSector: Healthcare

Total Revenue Growth

In the fourth quarter of 2023, CVS Health Corp's total revenues increased to $93.8 billion, marking an 11.9% rise compared to the same period in the previous year. This growth was driven by strong performance across all segments of the company.

Adjusted Earnings Per Share

For the fourth quarter of 2023, CVS Health Corp reported an adjusted earnings per share (EPS) of $2.12, which is an increase from the $2.04 adjusted EPS reported in the fourth quarter of 2022. This reflects a positive adjustment in the company's earnings performance.

Full-Year Revenue

For the full year ending December 31, 2023, CVS Health Corp's total revenues reached $357.8 billion, representing a 10.9% increase compared to the previous year. This substantial growth underscores the company's robust financial health and operational success over the year.

Dividend Increase

CVS Health Corp announced a 10% increase in its quarterly shareholder dividend, which took effect with the February 1, 2024 dividend distribution. In 2023, the company returned $3.1 billion to shareholders through dividends, highlighting its commitment to delivering value to its investors.

2024 Financial Guidance

Looking ahead, CVS Health Corp has revised its 2024 full-year guidance. The company now expects GAAP diluted EPS to be at least $7.06, down from the previous guidance of at least $7.26. Adjusted EPS guidance has also been revised to at least $8.30 from the earlier forecast of at least $8.50, reflecting anticipated challenges in the upcoming year.

Summarized from source with an LLMView Source

Key figures

-16.7%1Y

-39.0%3Y

-24.1%5Y

Performance

31.2%1Y

27.0%3Y

29.3%5Y

Volatility